Serum Institute To Make Sputnik V From Sept; 30 Crore Doses Expected Per Year

Mumbai: The Russian Direct Investment Fund (RDIF) and Serum Institute of India (SII) on Tuesday announced that Sputnik V COVID-19 vaccine’s production will commence at SII’s facilities in September.

While SII will start production of Sputnik V in September, Russian Direct Investment Fund (RDIF) CEO Kirill Dmitriev said other manufacturers are ready to produce the Russian-developed vaccine in India.

“The first batch of the Sputnik vaccine is expected to be produced at SII’s facilities in September,” an RDIF statement said.

Also Read: 3rd COVID Wave Will Not Come On Its Own, Says PM To People ‘Enjoying Before 3rd Wave’

“As part of the technology transfer process, SII has already received cell and vector samples from the Gamalia centre. With their import being cleared by the Drug Controller General of India (DCGI), the process of cultivation has started. ”

RDIF said that India plans to produce more than 300 million doses of the Sputnik V vaccine per year.

It may be noted that India has already started administering the Sputnik V vaccine – the third jab to be approved by the country after Covishield and Covaxin.

Meanwhile, Dr Reddy’s Laboratories Ltd announced yesterday that the Sputnik V vaccine is now available in 50 cities and towns across India.

Sputnik V has been developed by Russia’s Gamaleya National Research Institute of Epidemiology and Microbiology.

Follow us on Twitter, Instagram, and like us on Facebook for the latest updates and interesting stories.